Although ICI has been shown to improve disease outcomes in patients with EC [11], it has not been as effective as expected (the ORR (objective response rate) varied from 42% to 57%) even in highly immunogenic (high TMB, MMR deficiency, PD-L1 positivity) tumors [12,13]. The gene discussed is CD274; the disease is mismatch repair cancer syndrome 1.